Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors

被引:1
|
作者
Pinto, Patricia [1 ]
Shetty, Shrimati [1 ]
Lacroix-Desmazes, Sebastien [2 ,3 ,4 ,5 ,6 ]
Bayry, Jagadeesh [2 ,3 ,4 ,5 ,6 ]
Kaveri, Srini [2 ,3 ,4 ,5 ,6 ]
Ghosh, Kanjaksha [1 ]
机构
[1] Natl Inst Immunohaematol ICMR, 13th Floor,New Multistoreyed Bldg,KEM Hosp Campus, Bombay 400012, Maharashtra, India
[2] Ctr Rech Cordeliers, INSERM, UMRS 1138, Paris, France
[3] Univ Paris 06, UMRS 1138, Paris, France
[4] Univ Paris 05, UMRS 1138, Paris, France
[5] Lab Int Assoc INSERM, Paris, France
[6] ICMR, Paris, France
关键词
Haemophilia A; FVIII; Inhibitors; Autoantibodies; India; FACTOR-VIII INHIBITORS; PREVIOUSLY UNTREATED PATIENTS; RECOMBINANT FACTOR-VIII; RISK-FACTORS; ACQUIRED HEMOPHILIA; LUPUS ANTICOAGULANT; FACTOR-IX; HEPATITIS-C; EFFICACY; MARKERS;
D O I
10.1016/j.imlet.2015.09.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Diagnosis and management of haemophilia patients with inhibitors is often tricky due to the heterogeneous nature of the antibodies with regard to their kinetics, as well as the co-existence of other interfering antibodies. Plasma samples from severe haemophilia A patients from India with and without FVIII inhibitors were analysed for the presence of possible co-existing antibodies such as lupus anticoagulants (LA), anti-cardiolipin antibodies (ACLA), anti-132-glycoprotein-I (anti-beta 2-GP-I) antibodies, viral transfusion transmitted disease (HIV, HBsAg, HCV) related antibodies, anti-cyclic citrullinated peptides (anti-CCP), and anti-nuclear antibodies. A high incidence of LA and anti-HCV antibodies was detected in Indian haemophilia A patients similar to earlier reports. More importantly, a relatively high incidence of autoantibodies to nuclear antigens (18.62%) and anti-CCP antibodies (1.38%) associated with autoimmune disorders was also seen in these congenital haemophilia A patients with and without inhibitors. Knowledge on the antibody profile in these haemophilia patients especially in those with FVIII inhibitors along with correlation with the clinical manifestations and other risk factors for inhibitor development could possibly shed more light on the complex immune response in these patients. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 50 条
  • [31] THE SPECIFICITY OF THE ASSAY DETERMINES THE MEASUREMENT OF FVIII ANTIGEN LEVELS IN PATIENTS WITH SEVERE HAEMOPHILIA A
    Lavend'homme, R.
    Van Laer, C.
    Vandenbriele, C.
    Hermans, C.
    Lambert, C.
    Van Dievoet, M. A.
    Peerlinck, K.
    Jacquemin, M.
    HAEMATOLOGICA, 2021, 106 (09) : 9 - 9
  • [32] Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A
    Aznar, J. A.
    Moret, A.
    Ibanez, F.
    Vila, C.
    Cabrera, N.
    Mesa, E.
    Bonanad, S.
    HAEMOPHILIA, 2014, 20 (05) : 624 - 629
  • [33] Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A
    Lindgren, A
    Wadenvik, H
    Tengborn, L
    HAEMOPHILIA, 2002, 8 (05) : 644 - 648
  • [34] Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors
    Mahlangu, Johnny N.
    BIODRUGS, 2018, 32 (06) : 561 - 570
  • [35] Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors
    Johnny N. Mahlangu
    BioDrugs, 2018, 32 : 561 - 570
  • [36] LONG-TERM OUTCOMES WITH EMICIZUMAB PROPHYLAXIS FOR SEVERE HAEMOPHILIA A WITHOUT FVIII INHIBITORS: EFFICACY AND SAFETY ANALYSES FROM HAVEN 3 & 4
    Mahlangu, J.
    Jimenez-Yuste, V.
    Ventriglia, G.
    Niggli, M.
    Barlera, S.
    Hermans, C.
    Lehle, M.
    Chowdary, P.
    Jew, L.
    Windyga, J.
    Frenzel, L.
    Castaman, G.
    Pipe, S. W.
    HAEMOPHILIA, 2023, 29 : 95 - 96
  • [37] Quality of life in patients with severe haemophilia A and inhibitors on PDFVIII
    Furby, D.
    Phillott, A.
    Roy, A.
    Rangarajan, S.
    Alamelu, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 833 - 833
  • [38] Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22
    Vianello, F
    Radossi, P
    Tison, T
    Dazzi, F
    Tagariello, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (04) : 807 - 809
  • [39] Costs and utilization of haemophilia A and B patients with and without inhibitors
    Armstrong, P. E.
    Malone, D. C.
    Krishnon, S.
    Wessler, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 530 - 530
  • [40] Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors
    Sun, Shawn X.
    Wu, Yanyu
    McDermott, Michael
    van Keep, Marjolijn
    BLOOD, 2019, 134